March 12, 2018 Mustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition
February 6, 2018 Mustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor Conference
December 14, 2017 Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
December 11, 2017 Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial
December 4, 2017 Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies
November 14, 2017 Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
November 14, 2017 Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller